Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

This randomized trial evaluated the efficacy and safety of combining finerenone (a nonsteroidal mineralocorticoid receptor antagonist) with empagliflozin (an SGLT2 inhibitor) in patients with chronic kidney disease (CKD) and type 2 diabetes. Participants were assigned to receive finerenone alone, empagliflozin alone, or a combination of both. The primary outcome was the relative change in the urinary albumin to creatinine ratio (UACR) from baseline to 180 days. Results showed that combination therapy reduced UACR by 29% more than finerenone alone and 32% more than empagliflozin alone, with no unexpected adverse events. The findings support the simultaneous initiation of these therapies for greater albuminuria reduction.

This randomized trial evaluated the efficacy and safety of combining finerenone (a nonsteroidal mineralocorticoid receptor antagonist) with empagliflozin (an SGLT2 inhibitor) in patients with chronic kidney disease (CKD) and type 2 diabetes. Participants were assigned to receive finerenone alone, empagliflozin alone, or a combination of both. The primary outcome was the relative change in the urinary albumin to creatinine ratio (UACR) from baseline to 180 days. Results showed that combination therapy reduced UACR by 29% more than finerenone alone and 32% more than empagliflozin alone, with no unexpected adverse events. The findings support the simultaneous initiation of these therapies for greater albuminuria reduction.